Effects of mifepristone on uterine leiomyoma in premenopausal women a meta analysis

Mifepristone was effective in treating leiomyomas, and 2.5 mg of mifepristone administered daily for 3 or 6 months was the optimal dosage for leiomyoma treatment.

Like Comment

Authors

Qi Shen, M.D., Ying Hua, M.D., Ph.D., Wenxiao Jiang, M.D., Wenwen Zhang, M.D., Miaomiao Chen, M.D., Xueqiong Zhu, M.D., Ph.D.

Volume 100, Issue 6, Pages 1722-1726.e10, December 2013

Abstract

Objective:

To conduct a meta-analysis of the studies assessing the effects of mifepristone on the uterus, uterine leiomyoma, and leiomyoma-related symptoms in premenopausal women.

Design:

Meta-analysis.

Setting:

Centers for reproductive care.

Patient(s):

Premenopausal women who suffered from leiomyoma.

Intervention(s):

We identified all of the studies published before December 2012 that compared the status of patients with leiomyoma before and after treatment with mifepristone.

Main Outcome Measure(s):

Leiomyoma-related symptoms, uterine or leiomyoma volume, changes in endometrial thickness.

Result(s):

A meta-analytic technique was used to study 11 randomized controlled trials involving 780 women with symptomatic uterine leiomyomas. The subjects received 2.5–25 mg/d of mifepristone for 3–6 months. Mifepristone could effectively reduce uterine and leiomyoma volume and alleviate leiomyoma symptoms, including hypermenorrhea, the mean menstrual blood loss, pelvic pain, pelvic pressure, anemia, and dysmenorrhea. There was no significant difference in the rate of atypical endometrial hyperplasia between the mifepristone treatment group and the placebo group.

Conclusion(s):

Mifepristone significantly reduced uterine and leiomyoma volume and alleviated leiomyoma-related symptoms. We recommend 2.5 mg of mifepristone administered daily for 3 or 6 months as the optimum clinical treatment for leiomyoma. There is insufficient evidence that mifepristone treatment led to atypical endometrial hyperplasia.

Read the full text at: http://www.fertstert.org/article/S0015-0282(13)03005-7/fulltext


Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.